Robert is CEO of spinout company Immetacyte Ltd and Honorary Professor of Medical Oncology at the University of Manchester / The Christie Hospital. After medical school at Trinity College Cambridge and University College London, he undertook a PhD in Antibody Engineering with Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge. As Professor of Medical Oncology from 1998-2019, he developed a clinical and preclinical research program in immuno-oncology at the University of Manchester. He has been the coordinator of several major European Union consortia in adoptive cell therapy and has published widely in scientific and clinical journals.
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
- Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
- Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023